Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Geode Capital Management LLC increased its position in Verastem, Inc. (NASDAQ:VSTM – Free Report) by 67.6% during the third ...

RBC Capital raised the firm’s price target on Verastem (VSTM) to $16 from $13 and keeps an Outperform rating on the shares as part of a broader ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM – Research Report) today and set a price target of $9.00.

BTIG Research has recently reiterated Verastem Inc (VSTM) stock to Buy rating, as announced on December 31, 2024, according to Finviz. Earlier, on September 30, 2024, Guggenheim had initiated the ...

Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

Highlights,FDA grants Priority Review for new treatment combination in recurrent KRAS mutant LGSOC.,Phase 2 trial results ...

Under development at US pharma company Verastem Oncology (Nasdaq: VSTM), whose shares closed up 40.9% at $5.17 on Wednesday ...